5th Annual In-House Counsel Forum on Government Regulation of

Prescription Drug Pricing

The Premier Legal and Regulatory Drug Pricing Event
Legislation - Regulation - Compliance - Enforcement - Litigation

Thursday, March 15, 2007

About

The only conference that allows you to see the complete pricing and reimbursement picture --

There’s a new pricing and reimbursement paradigm – thanks to the DRA and the MMA. This new rebate model is far reaching, and goes well beyond price setting and reimbursement.

New pricing methodologies mean new compliance challenges…

Nearly every major component of the pharmaceutical industry, as well as public and private healthcare, is in a tailspin. R&D, IP, product and formulary placement, and patient access all have been touched by these reforms in some way.

More scrutiny under the DRA and Part D = more litigation?

These newest reforms are at the root of new and continuing anxieties over pricing transparency and fraud and abuse. They also exacerbate the scope of existing dilemmas, such as public and private pricing litigation and criminal enforcement actions. Will Medicare Part D pricing and AMP reform under the DRA bring something akin to the long-waged civil and criminal AWP suits?

How do your business operations need to change?

For five years, only one publication has brought the whole picture into focus: American Conference Institute’s In-House Counsel Forum on Government Regulation of Prescription Drug Pricing. Get full coverage of all the new developments, from all the leading experts.

Hear from those in the trenches of pricing and reimbursement, and hear first-hand how the new landscape is evolving.

Contents & Contributors

About

The only conference that allows you to see the complete pricing and reimbursement picture --

There’s a new pricing and reimbursement paradigm – thanks to the DRA and the MMA. This new rebate model is far reaching, and goes well beyond price setting and reimbursement.

New pricing methodologies mean new compliance challenges…

Nearly every major component of the pharmaceutical industry, as well as public and private healthcare, is in a tailspin. R&D, IP, product and formulary placement, and patient access all have been touched by these reforms in some way.

More scrutiny under the DRA and Part D = more litigation?

These newest reforms are at the root of new and continuing anxieties over pricing transparency and fraud and abuse. They also exacerbate the scope of existing dilemmas, such as public and private pricing litigation and criminal enforcement actions. Will Medicare Part D pricing and AMP reform under the DRA bring something akin to the long-waged civil and criminal AWP suits?

How do your business operations need to change?

For five years, only one publication has brought the whole picture into focus: American Conference Institute’s In-House Counsel Forum on Government Regulation of Prescription Drug Pricing. Get full coverage of all the new developments, from all the leading experts.

Hear from those in the trenches of pricing and reimbursement, and hear first-hand how the new landscape is evolving.

Contents & Contributors

HOSPITAL CLASS ACTION LAWSUITS
Melinda Reid Hatton, American Hospital Association (Washington, DC)

POSTURING THE CASE IN THE CLIENT’S FAVOR: ADVANCED STRATEGIC CONSIDERATIONS FOR ACHIEVING EARLY SUCCESS
John D. Aldock, Goodwin Procter LLP (Washington, DC)

POSTURING THE CASE IN THE CLIENT’S FAVOR: ADVANCED STRATEGIC CONSIDERATIONS FOR ACHIEVING EARLY SUCCESS
Grant C. Killoran, Michael Best & Friedrich LLP (Milwaukee, WI)

HEALTH-CARE ANTITRUST LITIGATION
John J. Miles, Ober Kaler Washington, DC)

ANTITRUST ISSUES IN PHARMACEUTICALS: PATENT SETTLEMENTS AND AUTHORIZED GENERICS
John Roberti, Mayer Brown Rowe & Maw (Washington, DC)

POSITIONING YOUR CASE FOR SUCCESS: MANAGING CRITICAL DISCOVERY ISSUES IN HEALTHCARE COMPLEX LITIGATION
Emily M. Yinger, Hogan & Hartson LLP (McLean, VA)
Pamela C. Williams, Esq., WellPoint, Inc. (Indianapolis, IN)

EXPLORING LITIGATION ALTERNATIVES AND DEVISING NOVEL END-GAME STRATEGIES IN HEALTHCARE COMPLEX LITIGATION: AN IN-HOUSE PERSPECTIVE
Elliot K. Gordon, WellPoint, Inc. (Thousand Oaks, CA)

QUI TAM LITIGATION OVERVIEW
Mitch Lazris, Hogan & Hartson LLP (Washington, DC)

QUI TAM AND YOU: SUCCESSFULLY LITIGATING HEALTH CARE FALSE CLAIMS ENFORCEMENT ACTIVITIES
Alan Bloom, Care 1st Health Plan (Alhambra, CA)

MANAGING RISK IN PARALLEL PROCEEDINGS
Wick Sollers III, King & Spalding (Washington, DC)

Ensuring Internal Policies and Procedures Address New Industry Risks
Howard J. Young, Sonnenschein Nath & Rosenthal LLP (Washington, DC)
Todd Kerr, Fresenius Medical Care, N.A. (Lexington, MA)



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0